Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Summary

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

Timeline

Start

2022-10-06

Primary completion

2024-01-11

Completion

2024-10-17

Outcome

Met primary endpoint

registry analysis (superiority test); Deucravacitinib vs Placebo; p <0.0001; Odds Ratio (OR) 6.2 (95% CI 2.5 to 15.3); Cochran-Mantel-Haenszel NCT05478499 ↗

release “In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16” bms.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	—	—

Indications